| TP53 altered in cohorts of …ALTERED_INderived54 of 54show fewer |
|---|
| → altered in cohorts of | Uterine Carcinosarcoma 52 / 57 cases (91 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Uterine Malignant Mixed Mesodermal (Mullerian) Tumor 52 / 57 cases (91 %) · ssm · ucs_tcga · largest of 3 cohorts | — | — | Uterine Malignant Mixed Mesodermal (Mullerian) Tumor | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Esophageal Carcinomasubtype 167 / 185 cases (90 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Lung Squamous Cell Carcinoma 453 / 504 cases (90 %) · ssm · TCGA-LUSC · largest of 7 cohorts | — | — | Lung Squamous Cell Carcinoma | 7 | Observed | gdc | graph → |
| → altered in cohorts of | Head and Neck Carcinoma, Other 96 / 108 cases (89 %) · ssm · ohnca_cptac_gdc | — | — | Head and Neck Carcinoma, Other | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Small Cell Carcinoma 103 / 120 cases (86 %) · ssm · sclc_ucologne_2015 · largest of 3 cohorts | — | — | Lung Small Cell Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Esophageal Adenocarcinoma 156 / 185 cases (84 %) · ssm · esca_tcga_gdc · largest of 4 cohorts | — | — | Esophageal Adenocarcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Ovarian Serous Cystadenocarcinoma 483 / 603 cases (80 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Head and Neck Squamous Cell Carcinomasubtype 392 / 528 cases (74 %) · ssm · TCGA-HNSC · largest of 7 cohorts | — | — | Head and Neck Squamous Cell Carcinoma | 7 | Observed | gdc | graph → |
| → altered in cohorts of | Rectal Adenocarcinoma 5,295 / 7,237 cases (73 %) · ssm · crc_msk_2026 · largest of 3 cohorts | — | — | Rectal Adenocarcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colorectal Adenocarcinoma 824 / 1,134 cases (73 %) · ssm · crc_msk_2017 · largest of 15 cohorts | — | — | Colorectal Adenocarcinoma | 15 | Observed | cbioportal | graph → |
| → altered in cohorts of | High-Grade Serous Ovarian Cancer 373 / 523 cases (71 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 5 cohorts | — | — | High-Grade Serous Ovarian Cancer | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | Chromophobe Renal Cell Carcinoma 59 / 86 cases (69 %) · ssm · TCGA-KICH · largest of 5 cohorts | — | — | Chromophobe Renal Cell Carcinoma | 5 | Observed | gdc | graph → |
| → altered in cohorts of | Skin Squamous Cell Carcinoma 55 / 83 cases (66 %) · ssm · cscc_ucsf_2021 · largest of 4 cohorts | — | — | Skin Squamous Cell Carcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Sarcomacancer_family 167 / 261 cases (64 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Gallbladder Carcinoma 154 / 244 cases (63 %) · ssm · gbc_mskcc_2022 · largest of 2 cohorts | — | — | Gallbladder Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Ampulla of Vater Carcinoma 99 / 160 cases (62 %) · ssm · ampca_bcm_2016 | — | — | Ampulla of Vater Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Skin Basal Cell Carcinoma 181 / 293 cases (62 %) · ssm · bcc_unige_2016 | — | — | Skin Basal Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Esophageal Squamous Cell Carcinoma 83 / 139 cases (60 %) · ssm · escc_ucla_2014 · largest of 2 cohorts | — | — | Esophageal Squamous Cell Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastroesophageal Junction Adenocarcinoma 309 / 518 cases (60 %) · ssm · stes_tcga_pub · largest of 6 cohorts | — | — | Gastroesophageal Junction Adenocarcinoma | 6 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colon Adenocarcinoma 237 / 429 cases (55 %) · ssm · coad_tcga_gdc · largest of 5 cohorts | — | — | Colon Adenocarcinoma | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Adenocarcinoma 1,429 / 2,653 cases (54 %) · ssm · luad_mskcc_2023_met_organotropism · largest of 17 cohorts | — | — | Lung Adenocarcinoma | 17 | Observed | cbioportal | graph → |
| → altered in cohorts of | Bladder Urothelial Carcinoma 245 / 474 cases (52 %) · ssm · blca_msk_tcga_2020 · largest of 19 cohorts | — | — | Bladder Urothelial Carcinoma | 19 | Observed | cbioportal | graph → |
| → altered in cohorts of | Osteosarcoma 70 / 145 cases (48 %) · ssm · TARGET-OS · largest of 2 cohorts | — | — | Osteosarcoma | 2 | Observed | gdc | graph → |
| → altered in cohorts of | Endometrial Carcinoma 850 / 1,882 cases (45 %) · ssm · ucec_ancestry_cds_msk_2023 · largest of 10 cohorts | — | — | Endometrial Carcinoma | 10 | Observed | cbioportal | graph → |
| → altered in cohorts of | Invasive Breast Carcinoma 1,707 / 3,879 cases (44 %) · ssm · breast_msk_2025 · largest of 23 cohorts | — | — | Invasive Breast Carcinoma | 23 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Non-Small Cell Carcinomasubtype 1,123 / 2,621 cases (43 %) · ssm · nsclc_ctdx_msk_2022 · largest of 8 cohorts | — | — | Lung Non-Small Cell Carcinoma | 8 | Observed | cbioportal | graph → |
| → altered in cohorts of | Combined Hepatocellular Carcinoma and Cholangiocarcinoma 74 / 173 cases (43 %) · ssm · hccihch_pku_2019 | — | — | Combined Hepatocellular Carcinoma and Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Diffuse Glioma 405 / 1,004 cases (40 %) · ssm · glioma_mskcc_2019 · largest of 17 cohorts | — | — | Diffuse Glioma | 17 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastric Adenocarcinoma 190 / 478 cases (40 %) · ssm · stad_tcga · largest of 6 cohorts | — | — | Gastric Adenocarcinoma | 6 | Observed | cbioportal | graph → |
| → altered in cohorts of | Uterine Corpus Sarcoma 40 / 108 cases (37 %) · ssm · usarc_msk_2020 | — | — | Uterine Corpus Sarcoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Pancreatic Adenocarcinoma 149 / 412 cases (36 %) · ssm · pancreas_ctdna_msk_2025 · largest of 10 cohorts | — | — | Pancreatic Adenocarcinoma | 10 | Observed | cbioportal | graph → |
| → altered in cohorts of | Pituitary Neuroendocrine Tumor 22 / 62 cases (35 %) · ssm · ptad_msk_2026 | — | — | Pituitary Neuroendocrine Tumor | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cholangiocarcinoma 147 / 417 cases (35 %) · ssm · chol_icgc_2017 · largest of 2 cohorts | — | — | Cholangiocarcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Hepatocellular Carcinoma 466 / 1,370 cases (34 %) · ssm · hcc_msk_2024 · largest of 10 cohorts | — | — | Hepatocellular Carcinoma | 10 | Observed | cbioportal | graph → |
| → altered in cohorts of | Malignant Breast Neoplasmcancer_family 58 / 174 cases (33 %) · ssm · CMI-MBC | — | — | Malignant Breast Neoplasm | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Appendix Adenocarcinoma 86 / 273 cases (32 %) · ssm · appendiceal_msk_2022 | — | — | Appendix Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Prostate Adenocarcinoma 551 / 2,069 cases (27 %) · ssm · prad_msk_stopsack_2021 · largest of 17 cohorts | — | — | Prostate Adenocarcinoma | 17 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cutaneous Melanoma 183 / 696 cases (26 %) · ssm · mel_mskimpact_2020 · largest of 4 cohorts | — | — | Cutaneous Melanoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Endometrioid Adenocarcinoma 61 / 247 cases (25 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Myeloid Neoplasm 32 / 136 cases (24 %) · ssm · mnm_washu_2016 | — | — | Myeloid Neoplasm | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Renal Pelvis and Ureter Urothelial Carcinoma 26 / 119 cases (22 %) · ssm · utuc_msk_2019 · largest of 2 cohorts | — | — | Renal Pelvis and Ureter Urothelial Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Angiosarcoma 23 / 129 cases (18 %) · ssm · angs_painter_2025 · largest of 2 cohorts | — | — | Angiosarcoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Intrahepatic Cholangiocarcinoma 70 / 412 cases (17 %) · ssm · ihch_msk_2021 · largest of 3 cohorts | — | — | Intrahepatic Cholangiocarcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | T-Cell Non-Hodgkin Lymphoma 21 / 132 cases (16 %) · ssm · mtnn_msk_2022 | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | B-Cell Non-Hodgkin Lymphoma 91 / 755 cases (12 %) · ssm · mbn_mdacc_2013 · largest of 3 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastrointestinal Stromal Tumor 20 / 183 cases (11 %) · ssm · gist_msk_2025 | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Myelodysplastic Syndromehematologic_malignancy 399 / 4,231 cases (9.4 %) · ssm · mds_mskcc_2020 · largest of 2 cohorts | — | — | Myelodysplastic Syndrome | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Diffuse Large B-Cell Lymphoma Unclassifiable 93 / 1,001 cases (9.3 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Acute Myeloid Leukemia 82 / 903 cases (9.1 %) · ssm · aml_ohsu_2022 · largest of 2 cohorts | — | — | Acute Myeloid Leukemia | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Small Lymphocytic Lymphoma 91 / 1,075 cases (8.5 %) · ssm · cll_broad_2022 · largest of 2 cohorts | — | — | Small Lymphocytic Lymphoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cervical Squamous Cell Carcinoma 23 / 291 cases (7.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts | — | — | Cervical Squamous Cell Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Adenoid Cystic Carcinoma 76 / 1,049 cases (7.2 %) · ssm · acc_2019 | — | — | Adenoid Cystic Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Ewing Sarcoma 21 / 290 cases (7.2 %) · ssm · es_dsrct_msk_2023 | — | — | Ewing Sarcoma | 1 | Observed | cbioportal | graph → |